Business Description
Altamira Therapeutics Ltd
NAICS : 541714
SIC : 2834
ISIN : CH0408330303
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.15 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.02 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 71.2 | |||||
3-Year EPS without NRI Growth Rate | 65.5 | |||||
3-Year FCF Growth Rate | 63 | |||||
3-Year Book Growth Rate | -80.3 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.38 | |||||
Quick Ratio | 1.38 | |||||
Cash Ratio | 0.69 | |||||
Days Inventory | 239.21 | |||||
Days Payable | 4009.33 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -272.7 | |||||
Shareholder Yield % | -69.62 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 6000 | |||||
Operating Margin % | 165775 | |||||
Net Margin % | 105650 | |||||
FCF Margin % | 397800 | |||||
ROA % | -56.21 | |||||
ROIC % | -73.76 | |||||
ROC (Joel Greenblatt) % | -2090.43 | |||||
ROCE % | -1206.39 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.74 | |||||
PB Ratio | 0.26 | |||||
Price-to-Tangible-Book | 0.65 | |||||
EV-to-EBIT | -0.32 | |||||
EV-to-EBITDA | -0.33 | |||||
EV-to-Revenue | -574.07 | |||||
EV-to-FCF | -0.18 | |||||
Earnings Yield (Greenblatt) % | -308.27 | |||||
FCF Yield % | -451.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Altamira Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | -0.003 | ||
EPS (TTM) (€) | -25.334 | ||
Beta | -0.07 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (€) | 0 | ||
20-Day SMA (€) | 948 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (€) | 948 - 948 | ||
Shares Outstanding (Mil) | 2.24 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Altamira Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Altamira Therapeutics Ltd Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Altamira Therapeutics Ltd Frequently Asked Questions
What is Altamira Therapeutics Ltd(FRA:2QA)'s stock price today?
When is next earnings date of Altamira Therapeutics Ltd(FRA:2QA)?
Does Altamira Therapeutics Ltd(FRA:2QA) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |